ArticleBMJ open2015
The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke.
Article in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Pooled it
- [Organization and costs of stroke care in outpatient settings: Systematic review].Atencion primaria · 2023Pooled it
- Health State Utility Values in People With Stroke: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2022Pooled it
- Self-reported quality of life following stroke: a systematic review of instruments with a focus on their psychometric properties.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Pooled it
- Economic Burden of Stroke Disease: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2020Pooled it
- A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.PharmacoEconomics · 2019Pooled it
- Economic burden of stroke: a systematic review on post-stroke care.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.PloS one · 2019Pooled it
- The economic burden of stroke: a systematic review of cost of illness studies.Journal of medicine and lifePooled it
- Trial
- A Cardiovascular Care Pathway Supported by Remote Patient Management in Dutch Primary Care: Cost-Effectiveness, Budget Impact, and Workload Analysis.JMIR mHealth and uHealth · 2026Article
- Clinical evidence on integrated Chinese-Western medicine for stroke rehabilitation.Integrative medicine research · 2026Article
- Real-world use of botulinum toxin-A for post-stroke spasticity in the Netherlands: a retrospective claims study.Journal of rehabilitation medicine · 2026Observational
- Article
- Prerequisites for Cost-Effective Home Blood Pressure Telemonitoring: Early Health Economic Analysis.JMIR cardio · 2025Article
- Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease.JTO clinical and research reports · 2025Article
- Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in The Netherlands.European heart journal. Quality of care & clinical outcomes · 2025Article
- Stroke survivors' long-term participation in paid employment.Work (Reading, Mass.) · 2024Article
- Associations between pre-stroke physical activity levels and health-related quality of life 3 months after stroke: A registry-based study (part of PAPSIGOT).International journal of stroke : official journal of the International Stroke Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess and explore over 1 year poststroke (1) the societal costs, (2) changes in costs and quality of life (QoL) and (3) the relation between costs and QoL.
designThe current study is a burden of disease study focusing on the cost-of-illness (in Euros) and QoL (in utilities) after stroke.
settingAdult patients with stroke were recruited from stroke units in hospitals and followed for 1 year.
participantsData were collected from 395 patients with stroke.
main outcome measuresCosts and QoL expressed in utilities.
methodsCost categories were identified through a bottom-up method. The Dutch 3-level 5-dimensional EuroQol (EQ-5D-3L) was used to calculate utilities. Non-parametric bootstrapping was applied to test for statistical differences in costs. Subgroup analyses were performed to identify predictors for costs and QoL. Robustness of results was tested via sensitivity analyses.
resultsThe total societal costs for 1 year poststroke were €29 484 (n=352) of which 74% were in the first 6 months. QoL remained stable over time. The discharge location was a significant predictor for cost and QoL; men had a significantly higher QoL than women and younger patients (<65) had significantly more costs than older patients (>65). Ceiling effects appear on all dimension of the EQ-5D-3L. Costs and QoL show a weak correlation (r=-0.29). Sensitivity analyses showed robustness of results.
conclusionsWe found lower patient costs and higher QoL than expected. This may be explained by the good state of health of our study population and by change in the Dutch healthcare system, which has led to considerable shorter hospitalisation poststroke. Future research must question the use of the EQ-5D-3L in a similar population due to ceiling effects. TRIAL REGISTRATION NUMBER: NTR3051.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.